Journal of Clinical Oncology, Vol 14, 814-820, Copyright © 1996 by American Society of Clinical Oncology

ARTICLES

Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group

G Giaccone, A Ardizzoni, A Kirkpatrick, M Clerico, T Sahmoud and N van Zandwijk
Free University Hospital, Netherlands Cancer Institute, Amsterdam.

BACKGROUND: Thymomas are rare neoplasms of the mediastinum. The role of chemotherapy in advanced thymomas is not fully established. PATIENTS AND METHODS: In the European Organization for Research and Treatment of Cancer (EORTC) Lung Cancer Cooperative Group, 16 patients with recurrent or metastatic malignant thymoma were entered over 6 years onto a study of combination chemotherapy that consisted of cisplatin 60 mg/m2 on day 1 and etoposide 120 mg/m2 on days 1, 2, and 3, every 3 weeks. RESULTS: A median of six courses per patient was administered. Main side effects of treatment were leukopenia, nausea and vomiting, and alopecia. Five complete responses and four partial responses were obtained, with a median response duration of 3.4 years. The median progression-free survival and survival times were 2.2 years and 4.3 years, respectively, with a median follow-up duration of 7 years. CONCLUSION: The combination of cisplatin and etoposide is highly effective and well tolerated in advanced thymoma. The investigation of this combination in a neoadjuvant setting in unresectable invasive thymoma is warranted.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. Tomaszek, D. A. Wigle, S. Keshavjee, and S. Fischer Thymomas: Review of Current Clinical Practice. Ann. Thorac. Surg., June 1, 2009; 87(6): 1973 - 1980. [Abstract] [Full Text] [PDF]

				C. D. Wright, N. C. Choi, J. C. Wain, D. J. Mathisen, T. J. Lynch, and P. Fidias Induction Chemoradiotherapy Followed by Resection for Locally Advanced Masaoka Stage III and IVA Thymic Tumors Ann. Thorac. Surg., February 1, 2008; 85(2): 385 - 389. [Abstract] [Full Text] [PDF]

				C. D. Wright, P. Fidias, N. C.H. Choi, J.-A. O. Shepard, and R. P. Hasserjian Case 16-2007 -- A 61-Year-Old Man with a Mediastinal Mass N. Engl. J. Med., May 24, 2007; 356(21): 2185 - 2193. [Full Text] [PDF]

				R. F. Riedel and W. R. Burfeind Jr Thymoma: Benign Appearance, Malignant Potential Oncologist, September 1, 2006; 11(8): 887 - 894. [Abstract] [Full Text] [PDF]

				F. C. Detterbeck and A. M. Parsons Thymic tumors Ann. Thorac. Surg., May 1, 2004; 77(5): 1860 - 1869. [Abstract] [Full Text] [PDF]

				Y. Iwasaki, S. Ohsugi, Y. Takemura, K. Nagata, H. Harada, and M. Nakagawa Multidisciplinary Therapy Including High-Dose Chemotherapy Followed by Peripheral Blood Stem Cell Transplantation for Invasive Thymoma Chest, December 1, 2002; 122(6): 2249 - 2252. [Abstract] [Full Text] [PDF]

				S. Umemura, Y. Segawa, K. Fujiwara, I. Takata, N. Seki, Y. Tokuda, K. Eguchi, and K. Mandai A Case of Recurrent Metastatic Thymoma Showing a Marked Response to Paclitaxel Monotherapy Jpn. J. Clin. Oncol., July 1, 2002; 32(7): 262 - 265. [Abstract] [Full Text] [PDF]

				C. R. Thomas, C. D. Wright, and P. J. Loehrer Thymoma: State of the Art J. Clin. Oncol., July 1, 1999; 17(7): 2280 - 2280. [Abstract] [Full Text] [PDF]

				D. Blumberg, M. E. Burt, M. S. Bains, R. J. Downey, N. Martini, V. Rusch, and R. J. Ginsberg Thymic Carcinoma: Current Staging Does Not Predict Prognosis J. Thorac. Cardiovasc. Surg., February 1, 1998; 115(2): 303 - 309. [Abstract] [Full Text] [PDF]

				J.-F. Regnard, F. Zinzindohoue, P. Magdeleinat, L. Guibert, L. Spaggiari, and P. Levasseur Results of Re-resection for Recurrent Thymomas Ann. Thorac. Surg., December 1, 1997; 64(6): 1593 - 1598. [Abstract] [Full Text]